+852 2866 8995 General Enquiry: cs@medikonia.com | Support: support@medikonia.com

Lonza CD19+ B Cells [Negatively selected]

Human CD19+ B cells isolated from peripheral blood using negative immunomagnetic selection, cryopreserved, ≥10 million cells. Catalog #: 4W-601

Product description Order information Resources Panel

Product Overview

Leukapheresed CD19+ B cells are negatively selected from leukapheresed peripheral blood MNCs using an immunomagnetic labeling system to remove unwanted cell types leaving the B cells untouched. Cells are cryopreserved in Lonza Cryo Media in a cryovial. Cell purity is determined post thaw using a FACS assay. Count and viability is determined using AO/PI. Cells are collected from healthy donors following IRB protocols.



  • Generating antibody libraries

  • Co-culture with T helper cells or cytotoxic lymphocytes (CTL)

  • B cell activation, clonal expansion, Ig rearrangement, and Ig secretion

  • Antigen presenting cell (APC) signal transduction and antigen presentation



1 vial containing ≥ 10 million cryopreserved cells


Recommended Media

Lonza X-VIVO™ 10 with L-glutamine, gentamicin and phenol red

Lonza X-VIVO™ 10 Serum-free Hematopoietic Cell Medium

Lonza X-VIVO™ 15 with L-glutamine, gentamicin, and phenol red

Lonza X-VIVO™ 15 Serum-free Hematopoietic Cell Medium, 500mL

Lonza X-VIVO™ 15 Serum-free Hematopoietic Cell Medium,1L

Lonza X-VIVO™ 15 with with L-glutamine, gentamicin, recombinant transferrin, and phenol red

Catalog #: 4W-601

Please email us at cs@medikonia.com for any enquiry. To place an order, please include the catalog number(s) of the product(s) in the email.